Home › Unified Patent Court › App_9038/2025

Zentiva K.S. vs. Accord Healthcare Ltd

App_9038/2025

Case Details

Case Number App_9038/2025

Patent Number

EP2501384 EP3501384

Filing Date 2025-02-28

Proceeding Type Generic

Case Phase Case Closed

Case Decision Date 28 February, 2025

Court Division Milan (IT) Central Division- Section

Parties & Representative

Claimants

Zentiva K.S.

Zentiva Portugal, LDA

Represented By

3 Representatives Listed

Gregory Bacon

Representative

Marc Lauzeral

Representative

Wim Maas

Representative

Defendants

Accord Healthcare Ltd

Accord Healthcare SLU

Novartis AG

Represented By

3 Representatives Listed

Gregory Bacon

Representative

Marc Lauzeral

Representative

Wim Maas

Representative

Court & Judges

Court / Division

Milan (IT) Central Division- Section

Judges

Andrea Postiglione

Marije Knijff

Oliver Werner

Patents Involved

2 Patents

There are 2 patents involved in this case.

Application Number	Patent Number	External Links
-	EP2501384	Espacenet Google Patents
-	EP3501384	Espacenet Google Patents

Docket Entries

Exhibit007 Marketing Authorization Estonian 200 mg

2025-02-28

No Actions

Exhibit029 Swarco v Strabag UPC Court of First Instance Vienna Judgment of 30 July 2024 Case No UPC CFI 33 2024

2025-02-28

No Actions

Exhibit008 Marketing Authorization Portugese 200 mg

2025-02-28

No Actions

Exhibit001 EP 2 501 384 B2

2025-02-28

No Actions

Exhibit013 Marketing Authorization Romania 150 mg

2025-02-28

No Actions

Exhibit019 Summary of product characteristics nilotinib Zentiva BG

2025-02-28

No Actions

Exhibit042 Akzo Nobel Chemicals and Akcros Chemicals v Commission CJEU 14 September 2010 Case C 550 07 P

2025-02-28

No Actions

Exhibit004 Marketing Authorization Latvia 150 mg

2025-02-28

No Actions

Exhibit024 Summary of product characteristics nilotinib Zentiva RO

2025-02-28

No Actions

Exhibit031 NEC v TCL UPC Court of First Instance Munich Order of 2 October 2024 Case No UPC CFI 487 2023

2025-02-28

No Actions

Exhibit022 Summary of product characteristics nilotinib Zentiva LV

2025-02-28

No Actions

Exhibit021 Summary of product characteristics nilotinib Zentiva LT

2025-02-28

No Actions

Exhibit008 Marketing Authorization Portugese 200 mg

2025-02-28

No Actions

Exhibit038 Director of the Spanish Agency of Medicines and Medical Devices n d Resolution on the termination of the mark

2025-02-28

No Actions

Exhibit046 Zentiva Portugal Certificate of incorporation

2025-02-28

No Actions

Exhibit024 Summary of product characteristics nilotinib Zentiva RO

2025-02-28

No Actions

Exhibit027 Ocado v Autostore UPC Court of Appeal Order of 10 January 2024 Case No UPC CoA 404 2023

2025-02-28

No Actions

Exhibit044 Novartis AG v Stada PI LG Munchen I Judgment of 4 December 2024 Case No 21 O 14559 24

2025-02-28

No Actions

Exhibit041 Artegodan GmbH v European Commission CJEU Third Chamber 19 April 2012 Case C 221 10 P

2025-02-28

No Actions

Exhibit014 Marketing Authorization Romania 200 mg

2025-02-28

No Actions

Exhibit011 Marketing Authorization Bulgaria 200 mg

2025-02-28

No Actions

Exhibit030 Seoul Viosys v Expert e Commerce UPC Court of First Instance Dusseldorf Judgment of 22 April 2024 Case No UPC

2025-02-28

No Actions

Exhibit037 CE Decision revoking Decision C 2022 3252

2025-02-28

No Actions

Exhibit030 Seoul Viosys v Expert e Commerce UPC Court of First Instance Dusseldorf Judgment of 22 April 2024 Case No UPC

2025-02-28

No Actions

Exhibit029 Swarco v Strabag UPC Court of First Instance Vienna Judgment of 30 July 2024 Case No UPC CFI 33 2024

2025-02-28

No Actions

Exhibit038 Director of the Spanish Agency of Medicines and Medical Devices n d Resolution on the termination of the mark

2025-02-28

No Actions

Exhibit045 Zentiva k s Certificate of incorporation

2025-02-28

No Actions

Exhibit026 Directive 2001 83 EC

2025-02-28

No Actions

Exhibit010 Marketing Authorization Portugese 50 mg

2025-02-28

No Actions

Exhibit046 Zentiva Portugal Certificate of incorporation

2025-02-28

No Actions

Exhibit009 Marketing Authorization Portugese 150 mg

2025-02-28

No Actions

Exhibit022 Summary of product characteristics nilotinib Zentiva LV

2025-02-28

No Actions

Exhibit019 Summary of product characteristics nilotinib Zentiva BG

2025-02-28

No Actions

Exhibit020 Summary of product characteristics nilotinib Zentiva EE

2025-02-28

No Actions

Exhibit036 Commission v Pharmaceutical Works Polpharma S A et al CJEU 16 March 2023 joined cases C 438 21 P to C 440 21

2025-02-28

No Actions

Exhibit018 Action brought on 21 October 2024 Novartis Europharm v Commission Case T 547 24 C 2025 396

2025-02-28

No Actions

Exhibit005 Marketing Authorization Latvia 200 mg

2025-02-28

No Actions

Exhibit023 Summary of product characteristics nilotinib Zentiva PT

2025-02-28

No Actions

Exhibit017 Novartis second offer for a non exclusive licensee from 20240724

2025-02-28

No Actions

Exhibit016 Novartis first for a non exclusive licensee from 20210706

2025-02-28

No Actions

Exhibit023 Summary of product characteristics nilotinib Zentiva PT

2025-02-28

No Actions

Exhibit034 Novartis AG v Aliud Pharma LG Munchen I Judgment of 4 December 2024 Case No 21 O 14559 24

2025-02-28

No Actions

Exhibit006 Marketing Authorization Estonian 150 mg

2025-02-28

No Actions

Exhibit013 Marketing Authorization Romania 150 mg

2025-02-28

No Actions

Exhibit033 MediaTek v Daedalus Prime LLC UPC Court of Appeal Order of 8 January 2025 Case No UPC CoA 621 2024

2025-02-28

No Actions

Exhibit009 Marketing Authorization Portugese 150 mg

2025-02-28

No Actions

Exhibit012 Marketing Authorization Bulgaria 150 mg

2025-02-28

No Actions

Exhibit010 Marketing Authorization Portugese 50 mg

2025-02-28

No Actions

Exhibit025 Regulation EC No 726 2004

2025-02-28

No Actions

Exhibit039 Director of the Spanish Agency of Medicines and Medical Devices n d Resolution on the termination of the mar

2025-02-28

No Actions

Exhibit020 Summary of product characteristics nilotinib Zentiva EE

2025-02-28

No Actions

Exhibit044 Novartis AG v Stada PI LG Munchen I Judgment of 4 December 2024 Case No 21 O 14559 24

2025-02-28

No Actions

Exhibit040 European Ferries and Diputacion Foral de Vizcaya v Commission CJEU 1 June 2006 joined Cases C 442 03 P and C

2025-02-28

No Actions

Exhibit028 Insulet Menarini UPC Court of First Instance Milan Procedural Order of 23 December 2024 Case No UPC CFI 380 2

2025-02-28

No Actions

Exhibit007 Marketing Authorization Estonian 200 mg

2025-02-28

No Actions

Exhibit011 Marketing Authorization Bulgaria 200 mg

2025-02-28

No Actions

Application

2025-02-28

No Actions

Exhibit006 Marketing Authorization Estonian 150 mg

2025-02-28

No Actions

Exhibit034 Novartis AG v Aliud Pharma LG Munchen I Judgment of 4 December 2024 Case No 21 O 14559 24

2025-02-28

No Actions

Exhibit021 Summary of product characteristics nilotinib Zentiva LT

2025-02-28

No Actions

Exhibit043 Insulet v Menarini UPC Court of First Instance Milan Procedural Order of 1 October 2024 Case No UPC CFI 380 2

2025-02-28

No Actions

Exhibit012 Marketing Authorization Bulgaria 150 mg

2025-02-28

No Actions

Exhibit032 Dolby v HP Deutschland UPC Court of First Instance Dusseldorf Judgment of 26 June 2024 Case No UPC CFI 457 20

2025-02-28

No Actions

Exhibit015 Marketing Authorization Lituania 150 mg and 200 mg

2025-02-28

No Actions

Exhibit032 Dolby v HP Deutschland UPC Court of First Instance Dusseldorf Judgment of 26 June 2024 Case No UPC CFI 457 20

2025-02-28

No Actions

Exhibit035 STADAPHARM v Novartis and Accord Healthcare UPC Court of First Instance Milan Preliminary Order of 3 February

2025-02-28

No Actions

Exhibit002 SmPC Tasigna Novartis

2025-02-28

No Actions

Exhibit039 Director of the Spanish Agency of Medicines and Medical Devices n d Resolution on the termination of the mar

2025-02-28

No Actions

Exhibit045 Zentiva k s Certificate of incorporation

2025-02-28

No Actions

Exhibit003 SmPC nilotinib Accord Healthcare

2025-02-28

No Actions

Exhibit014 Marketing Authorization Romania 200 mg

2025-02-28

No Actions

PRELIMINARY ORDER 1st MARCH

2025-03-01

No Actions

Template-Order

2025-03-01

No Actions

Written submission on request to intervene by Zentiva

2025-03-17

No Actions

EN pdf 1

2025-03-21

Download

Headnote-and-Keywords

2025-03-27

No Actions

Outcome of the Order

2025-03-27

No Actions

ORDER 27 MARCH 2025

2025-03-27

Download

EN pdf 1

2025-07-31

Download